SCHEMBL6548265

SCHEMBL6548265

O=Cc1ccc(CCCCOc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
S1PR1 P21453 8/20 0.35
S1PR3 Q99500 5/20 0.35
HTT P42858 1/20 0.34
CYP1A2 P05177 2/20 0.33
RAB9A P51151 1/20 0.32
FFAR1 O14842 1/20 0.32
PLA2G4A P47712 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
ALOX12 P18054 1/20 0.32
MAPK1 P28482 1/20 0.32
RECQL P46063 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6548477 0.96 HPGD (0.37) HPGDALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL6547928 0.93 ALDH1A1 (0.35) HPGDALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL6547674 0.89 ALDH1A1 (0.42) HPGDALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL6550048 0.88 ALDH1A1 (0.41) HPGDALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL8408013 0.88 IGF1R (0.39) HPGDALDH1A1MAPTLMNAS1PR1
SCHEMBL5605592 0.87 ALDH1A1 (0.45) HPGDALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL8658987 0.86 PPARA (0.39) MAPTS1PR1S1PR3HTTCYP1A2
SCHEMBL6548563 0.85 CYP1A2 (0.41) HPGDALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL8405678 0.85 S1PR1 (0.41) HPGDALDH1A1LMNAS1PR1S1PR3
SCHEMBL6550042 0.85 HTT (0.42) HPGDALDH1A1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 HPGD 881/4885ALDH1A1 513/4885MAPT 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.